Muhammad Furqan MD

Oncology•Iowa City, IA

Head & Neck Cancer, Hematologic Oncology, Thoracic Cancer

Clinical Assistant Professor

Join to View Full Profile

200 Hawkins DrDept of Internal Medicine C32 GHIowa City, IA 52242
Phone+1 319-356-1527
Fax+1 319-353-8383

Education & Training

Westchester Medical CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Rutgers Health/New Jersey Medical SchoolResidency, Internal Medicine, 2008 - 2011
Dow University of Health SciencesClass of 2005

Certifications & Licensure

IA State Medical License 2014 - 2026
NJ State Medical License 2009 - 2013
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Pharmacological Ascorbate for Lung Cancer
COMPLETED
PHASE2
Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer Start of enrollment: 2016 Aug 29
ACTIVE_NOT_RECRUITING
PHASE2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
ACTIVE_NOT_RECRUITING
PHASE3
PDR001 + Panobinostat for Melanoma and NSCLC Start of enrollment: 2019 Sep 01
Withdrawn
Phase 1
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2021 Apr 20
RECRUITING
PHASE2
Roles: Principal Investigator, Contact, Sponsor-Investigator
Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer Start of enrollment: 2021 Aug 21
ACTIVE_NOT_RECRUITING
Roles: Contact
A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC Start of enrollment: 2018 Nov 16
RECRUITING
PHASE2
Roles: Contact, Principal Investigator
Ascorbate with Durvalumab in Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2023 Oct 23
RECRUITING
PHASE1
Roles: Sponsor-Investigator, Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Safety and Tolerability of Lete-cel in NSCLC-Reply.
Mehmet Altan, Gilberto Lopes, T Jeroen N Hiltermann, Ramaswamy Govindan, Liza C Villaruz
Clinical Cancer Research. 2025-05-01
2 citations
Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung Cancer.
Mehmet Altan, Gilberto Lopes, T Jeroen N Hiltermann, Ramaswamy Govindan, Liza C Villaruz
Clinical Cancer Research. 2025-02-03
Phase Ib/II study of imprime PGG and pembrolizumab in patients with previously treated advanced non-small cell lung cancer (NSCLC): BTCRC LUN 15-017.
Muhammad Furqan, Jyoti Malhotra, Ardaman Shergill, Li Liu, Sarah L Mott
Translational Lung Cancer Research. 2024-11-30

Abstracts/Posters

[Board 555] Effect of Anakinra on Colchicine Resistant and Steroid Dependent Recurrent Pericarditis: A Systemic Review and Meta-Analysis
Muhammad Furqan, 2019 ACC Scientific Session & Expo, New Orleans, New Orleans, 3/18/2019

Press Mentions

Conspiracy Theories Are the Reason We Still Have PolioMarch 17th, 2017

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Muhammad Furqan MD

Dr. Furqan is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.